Emerging evidence indicates that ARID1A mutations serve as an independent prognostic biomarker, with loss-of-function variants significantly associated with reduced cancer-specific survival, increased recurrence rates (9) and diminished therapeutic response (14). This evidence concerns the gene ARID1A and cancer.